

The Melanocortin Receptors

The Receptors

Series Editor

David B. Bylund

University of Nebraska Medical Center, Omaha, NE

Board of Editors

S. J. Enna

*University of Kansas
Kansas City, Kansas*

Bruce S. McEwen

*Rockefeller University
New York, New York*

Morley D. Hollenberg

*University of Calgary
Calgary, Alberta, Canada*

Solomon H. Snyder

*Johns Hopkins University
Baltimore, Maryland*

The Melanocortin Receptors,
edited by *Roger D. Cone*, 2000
The GABA Receptors, Second
Edition, edited by *S. J. Enna and
Norman G. Bowery*, 1997
The Ionotropic Glutamate Receptors,
edited by *Daniel T. Monaghan and
Robert Wenthold*, 1997
The Dopamine Receptors, edited by
*Kim A. Neve and
Rachael L. Neve*, 1997
**The Metabotropic Glutamate
Receptors,** edited by *P. Jeffrey
Conn and Jitendra Patel*, 1994
The Tachykinin Receptors, edited
by *Stephen H. Buck*, 1994

The Beta-Adrenergic Receptors,
edited by *John P. Perkins*, 1991
Adenosine and Adenosine Receptors,
edited by *Michael Williams*, 1990
The Muscarinic Receptors, edited
by *Joan Heller Brown*, 1989
The Serotonin Receptors, edited
by *Elaine Sanders-Bush*, 1988
The Alpha-2 Adrenergic Receptors,
edited by *Lee Limbird*, 1988
The Opiate Receptors, edited
by *Gavril W. Pasternak*, 1988
The Alpha-1 Adrenergic Receptors,
edited by *Robert R. Ruffolo, Jr.*, 1987
The GABA Receptors, edited
by *S. J. Enna*, 1983

The Melanocortin Receptors

Edited by

Roger D. Cone

*Vollum Institute, Oregon Health Sciences University
Portland, OR*



**Springer Science+Business
Media, LLC**

© 2000 Springer Science+Business Media New York
Originally published by Humana Press Inc. in 2000
Softcover reprint of the hardcover 1st edition 2000

All rights reserved.

No part of this book may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, microfilming, recording, or otherwise without written permission from the Publisher.

All authored papers, comments, opinions, conclusions, or recommendations are those of the author(s), and do not necessarily reflect the views of the Publisher.

This publication is printed on acid-free paper. ©
ANSI Z39.48-1984 (American National Standards Institute) Permanence of Paper for Printed Library Materials.

For additional copies, pricing for bulk purchases, and/or information about other Humana titles, contact Humana at the above address or at any of the following numbers: Tel.: 973-256-1699; Fax: 973-256-8341; E-mail: humana@humanapr.com

Cover design by Roger D. Cone and Linda Cordilia.

Photocopy Authorization Policy:

Authorization to photocopy items for internal or personal use, or the internal or personal use of specific clients, is granted by Springer Science+Business Media, LLC, provided that the base fee of US \$10.00 per copy, plus US \$00.25 per page, is paid directly to the Copyright Clearance Center at 222 Rosewood Drive, Danvers, MA 01923. For those organizations that have been granted a photocopy license from the CCC, a separate system of payment has been arranged and is acceptable to Springer Science+Business Media, LLC

10 9 8 7 6 5 4 3 2 1

ISBN 978-1-61737-082-3 ISBN 978-1-59259-031-5 (eBook)
DOI 10.1007/978-1-59259-031-5

Library of Congress Cataloging in Publication Data

Main entry under title:

The melanocortin receptors / edited by Roger D. Cone.

p. cm. -- (The Receptors)

Includes bibliographical references and index.

1. MSH (Hormone)--Receptors. 2. Proopiomelanocortin--Receptors.

I. Cone, Roger D. II. Series.

[DNLM: 1. Receptors, Corticotropin--physiology. WK 515 M5165 2000]

QP572.M75M44 2000

573.4'54--dc21

DNLM/DLC

for Library of Congress

99-38475

CIP

Preface

The melanocortins have a fascinating history, first as pituitary peptide hormones, and more recently as neuropeptides. The study of the melanocortin peptides and their receptors has contributed many “firsts” to biomedical research. Based on the frog skin pigmentation assay, melanotropic activity was first identified in pituitary extracts early in this century; in many ways these experiments heralded the beginning of modern pituitary endocrinology. The melanocortin peptides were also among the first biologically active peptides to be purified and sequenced in the 1950s by Bell, Lerner, Li, Harris, and Geschwind. Cloning of the complete proopiomelanocortin precursor gene by Nakanishi and Numa in 1979 provided one of the first examples of a prohormone precursor encoding a variety of different neuropeptides and peptide hormones.

More recently, work in the field has largely been focused on the receptors for the melanocortin peptides. My own interest in receptors for the melanocortin peptides derived from a structural question rather than any knowledge of, or interest in, the biology of these peptides. In 1989, the structure of the luteinizing hormone receptor was published, and this made it clear that the large glycoprotein hormones were binding to a large extracellular domain attached to the canonical hydrophobic seven-membrane spanning domain known at the time to be the conserved structure for such G-protein coupled receptors as rhodopsin, the β -adrenergic receptor, and the substance K receptor. Though the substance K receptor clearly was capable of binding the hydrophilic substance P peptide without a large extracellular domain, I remember many discussions among scientists at the time, particularly John Potts and Henry Kronenberg at the MGH, that perhaps the extracellular motif of the glycoprotein hormone receptors was a conserved domain that could be involved in the binding of many large peptide hormones such as PTH and ACTH. Ultimately, Kathleen Mountjoy in my laboratory, with important reagents from Jeff Tatro and Seymour Reichlin, Vijay Chhajlani in Sweden, and Ira Gantz at the University of Michigan were able to disprove this hypothesis with the cloning of a family of five different receptors for the melanocortin peptides.

Around the time of the cloning of the melanocortin receptors, there was skepticism about whether many interesting biological findings would result from continued studies of the melanocortin receptors. The mechanism of action of the MSH-R and ACTH-R in pigmentation and adrenal steroidogen-

esis, for example, seemed to be fairly well understood. Happily, over the last eight years, around every corner a remarkable new finding has arisen regarding the melanocortin receptors, their mode of action, and their physiological roles. Continuing with the listing of “firsts,” the MC1-R was the first example of a G-protein-coupled hormone receptor to be constitutively activated by naturally occurring mutations, the agouti and agouti-related proteins are the first examples of endogenous antagonists of the GPCRs, and the MC4-R is the first GPCR to be demonstrated to be involved in the central control of energy homeostasis. If the annual number of publications in the melanocortin field is any indicator, the tenfold increase over the last five years suggests a tremendous newfound interest in the remarkable complexity of action and function of the melanocortins.

Organizing *The Melanocortin Receptors* has given much pleasure owing to the many fine colleagues I have had the privilege of working with, quite a number of whom have provided chapters for this volume. I would like to express my sincere thanks to the authors, and to the editors at Humana Press for making this book happen. Finally, I thank my wife Midge and children Miriam, Anna, and David for their continued encouragement and patience, and for genuinely sharing in the excitement of scientific discovery.

Roger D. Cone

Contents

Preface v
Contributors ix

PART I. HISTORICAL PERSPECTIVES

1 • Proopiomelanocortin and the Melanocortin Peptides 3
Alex N. Eberle
2 • Melanocortins and Pigmentation 69
Aaron B. Lerner
3 • Melanocortins and Adrenocortical Function 75
Martine Bégeot and José M. Saez
4 • Effects of Melanocortins in the Nervous System 109
Roger A. H. Adan
5 • Peripheral Effects of Melanocortins 143
Bruce A. Boston

PART II. CHARACTERIZATION OF THE MELANOCORTIN RECEPTORS

6 • Melanocortin Receptor Expression and Function
in the Nervous System 173
Jeffrey B. Tatro
7 • Cloning of the Melanocortin Receptors 209
Kathleen G. Mountjoy

PART III. BIOCHEMICAL MECHANISM OF RECEPTOR ACTION

8 • The Molecular Pharmacology of Alpha-Melanocyte Stimulating
Hormone: *Structure–Activity Relationships for Melanotropins*
at Melanocortin Receptors 239
Victor J. Hruby and Guoxia Han
9 • In Vitro Mutagenesis Studies of Melanocortin Receptor
Coupling and Ligand Binding 263
Carrie Haskell-Luevano

PART IV. RECEPTOR FUNCTION

- 10 • The Melanocortin-1 Receptor 309
*Dongsi Lu, Carrie Haskell-Luevano, Dag Inge Vage,
 and Roger D.Cone*
- 11 • The Human Melanocortin-1 Receptor 341
Eugene Healy, Mark Birch-Machin, and Jonathan L. Rees
- 12 • The Melanocortin-2 Receptor in Normal Adrenocortical Function
 and Familial Adrenocorticotropic Hormone Resistance 361
Adrian J. L. Clark
- 13 • The Melanocortin-3 Receptor 385
Robert A. Kesterson
- 14 • The Melanocortin-4 Receptor 405
Roger D. Cone
- 15 • The Melanocortin-5 Receptor 449
Wenbiao Chen

PART V. RECEPTOR REGULATION

- 16 • Regulation of the Melanocortin Receptors by Agouti 475
William O. Wilkison
- 17 • Melanocortins and Melanoma 491
Alex N. Eberle, Sylvie Froidevaux, and Walter Siegrist
- 18 • Regulation of the Mouse and Human
 Melanocortin-1 Receptor 521
Zalfa Abdel-Malek

PART VI. FUTURE VISTAS

- 19 • Future Vistas 539
Roger D. Cone

- Index 547

Contributors

ZALFA ABDEL-MALEK • *Department of Dermatology, University of Cincinnati Medical Center, Cincinnati, OH*

ROGER A. H. ADAN • *Rudolf Magnus Institute for Neuroscience, Utrecht University, Utrecht, Netherlands*

MARTINE BÉGEOT • *Hospital Debrousse, Lyon, France*

MARK BIRCH-MACHIN • *Department of Dermatology, University of Newcastle, Newcastle, UK*

BRUCE A. BOSTON • *Department of Pediatrics, Oregon Health Sciences University, Portland, Oregon*

WENBIAO CHEN • *Massachusetts Institute of Technology Center for Cancer Research, Cambridge, MA*

ROGER D. CONE • *Vollum Institute, Oregon Health Sciences University, Portland, Oregon*

ADRIAN J. L. CLARK • *Department of Chemical Endocrinology, St. Bartholomews Hospital, London, UK*

ALEX N. EBERLE • *Department of Research, University Hospital, Basel, Switzerland*

SILVIE FROIDEVAUX • *Department of Research, University Hospital, Basel, Switzerland*

CARRIE HASKELL-LUEVANO • *Department of Medicinal Chemistry, University of Florida, Gainesville, FL*

EUGENE HEALY • *Department of Dermatology and Dermatopharmacology, Southampton General Hospital, Southampton, UK*

GUOXIA HAN • *Department of Chemistry, University of Arizona, Tucson, AZ*

VICTOR J. HRUBY • *Department of Chemistry, University of Arizona, Tucson, AZ*

ROBERT A. KESTERSON • *Department of Molecular Physiology and Biophysics, Vanderbilt University School of Medicine, Nashville, TN*

AARON B. LERNER • *Department of Dermatology, Yale University School of Medicine, New Haven, CT*

DONGSI LU • *Department of Pathology, Washington University School of Medicine, St Louis, MO*

KATHLEEN G. MOUNTJOY • *Research Center for Developmental Medicine and Biology, University of Auckland, Auckland, New Zealand*

JONATHAN L. REES • *Department of Medical and Radiological Sciences, University of Edinburgh, Edinburgh, UK*

JOSÉ M. SAEZ • *Hospital Debrousse, Lyon, France*

WALTER SIEGRIST • *Department of Research, University Hospital,
Basel, Switzerland*

JEFFREY B. TATRO • *Endocrine Division, New England Medical Center
Hospital, and Tufts University School of Medicine, Boston, MA*

DAG INGE VAGE • *Department of Animal Science, Agricultural University
of Norway, Norway*

WILLIAM O. WILKISON • *Zen-Bio Inc., Research Triangle Park, NC*